{"html":"

  • Timing is everything in combination therapy for osteoporosis<\/a><\/h3>The adult human skeleton undergoes constant remodeling, with new bone forming at sites that have been broken down by a precise process called resorption.<\/summary><\/li>

  • Osteoporosis drug builds bone in patients with gum disease<\/a><\/h3>A drug marketed to grow bone in osteoporosis patients also works to heal bone wounds in gum disease patients, a University of Michigan study suggests.<\/summary><\/li>

  • Devastating impact of spinal osteoporotic fractures revealed on World Osteoporosis Day<\/a><\/h3>A new report issued by the International Osteoporosis Foundation (IOF) for World Osteoporosis Day puts the spotlight on the severe impact of spinal fractures and calls on health professionals to recognize the signs of these fractures in their patients.<\/summary><\/li>

  • Vitamin D deficiency puts IBD patients at greater risk of osteoporosis<\/a><\/h3>Vitamin D deficiency puts patients with Inflammatory Bowel Disease (IBD) at greater risk of osteoporosis, osteopenia and an overall higher rate of abnormal bone density, according to the results of a new study unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.<\/summary><\/li>

  • Older women with normal T-scores may not need bone mineral density screening for 10 years<\/a><\/h3>Since 2002, the U.S. Preventive Services Task Force has recommended that women ages 65 and older be routinely screened for osteoporosis and has suggested that a 2-year screening interval might be appropriate.<\/summary><\/li>

  • Drugs treating Osteoporosis may cause bone fractures: FDA<\/a><\/h3>Taking drugs to prevent bone breakage may actually increase the chances for an unusual type of thigh bone fracture, Food and Drug Administration officials warned Wednesday.<\/summary><\/li>

  • FDA: Possible increased risk of thigh bone fracture with bisphosphonates<\/a><\/h3>The U.S. Food and Drug Administration today warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates, a class of drugs used to prevent and treat osteoporosis. A labeling change and Medication Guide will reflect this risk.<\/summary><\/li>

  • IOF campaign puts spotlight on vastly under-diagnosed and under-treated spinal fractures<\/a><\/h3>At a press conference held in Brussels today, the International Osteoporosis Foundation (IOF), the Belgian Bone Club and the European Parliament Osteoporosis Interest Group called on health care professionals and health policy officials in Europe to take action to prevent spinal fractures.<\/summary><\/li>

  • Warner Chilcott announces FDA approval of next generation Actonel<\/a><\/h3>Warner Chilcott plc today announced that the United States Food and Drug Administration (FDA) has approved its next generation ACTONEL\u00c2\u00ae (risedronate sodium) product for the treatment of postmenopausal osteoporosis in the United States.<\/summary><\/li>

  • Controlling bone formation to prevent osteoporosis<\/a><\/h3>Aging disrupts the balance between bone formation and bone destruction, resulting in osteoporosis, which is characterized by reduced bone mass and increased risk of fracture.<\/summary><\/li>"}